These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20585136)

  • 1. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
    Nguyen HT; Sheu TG; Mishin VP; Klimov AI; Gubareva LV
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3671-7. PubMed ID: 20585136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
    Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
    Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
    Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
    Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
    Meijer A; Rebelo-de-Andrade H; Correia V; Besselaar T; Drager-Dayal R; Fry A; Gregory V; Gubareva L; Kageyama T; Lackenby A; Lo J; Odagiri T; Pereyaslov D; Siqueira MM; Takashita E; Tashiro M; Wang D; Wong S; Zhang W; Daniels RS; Hurt AC
    Antiviral Res; 2014 Oct; 110():31-41. PubMed ID: 25043638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
    Marjuki H; Mishin VP; Sleeman K; Okomo-Adhiambo M; Sheu TG; Guo L; Xu X; Gubareva LV
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5209-15. PubMed ID: 23917311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
    Stoner TD; Krauss S; DuBois RM; Negovetich NJ; Stallknecht DE; Senne DA; Gramer MR; Swafford S; DeLiberto T; Govorkova EA; Webster RG
    J Virol; 2010 Oct; 84(19):9800-9. PubMed ID: 20660186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011-2012 influenza season.
    Murtaugh W; Mahaman L; Healey B; Peters H; Anderson B; Tran M; Ziese M; Carlos MP
    Public Health Rep; 2013; 128 Suppl 2(Suppl 2):75-87. PubMed ID: 23997307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro neuraminidase inhibitory concentration (IC
    Ikematsu H; Kawai N; Tani N; Chong Y; Bando T; Iwaki N; Kashiwagi S
    J Infect Chemother; 2020 Aug; 26(8):775-779. PubMed ID: 32249161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
    Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
    J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
    Ikematsu H; Kawai N; Kashiwagi S
    J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
    Okomo-Adhiambo M; Hurt AC; Gubareva LV
    Methods Mol Biol; 2012; 865():95-113. PubMed ID: 22528155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.
    Nguyen HT; Trujillo AA; Sheu TG; Levine M; Mishin VP; Shaw M; Ades EW; Klimov AI; Fry AM; Gubareva LV
    Antiviral Res; 2012 Mar; 93(3):381-6. PubMed ID: 22330888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of influenza resistance to the neuraminidase inhibitors.
    Thorlund K; Awad T; Boivin G; Thabane L
    BMC Infect Dis; 2011 May; 11():134. PubMed ID: 21592407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.